Patent · US Active

Pyrrolo and pyrazolopyrimidines as ubiquitin-specific protease 7 inhibitors

US9902728B2 · kind B2 · utility

21Cited by

59References

40Claims

0Family size

Assignee

FORMA Therapeutics, Inc. · US

Inventors

Stephanos Ioannidis · Natick, US
Adam Charles Talbot · Guilford, US
Bruce Follows · Littleton, US
Alexandre Joseph Buckmelter · Superior, US
Minghua Wang · Acton, US
Ann-Marie Campbell · Monroe, US
Darby Schmidt · Arlington, US
David Joseph Guerin · Natick, US
Justin Andrew Caravella · Cambridge, US
R. Bruce Diebold · Waltham, US
Anna Ericsson · Keyano, CA
David R. Lancia, Jr. · Boston, US

Key dates

Filing date	Dec 29, 2015
Grant date	Feb 27, 2018
Priority date	—
Expiry date	Dec 29, 2035

Classification

Technology area (CPC Y)Emerging Cross-Sectional Technologies
CPC primaryY02A50/30
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The invention relates to inhibitors of USP7 inhibitors useful in the treatment of cancers, neurodegenerative diseases, immunological disorders, inflammatory disorders, cardiovascular diseases, ischemic diseases, viral infections and diseases, and bacterial infections and diseases, having the Formula:where m, n, X1, X2, R1-R5, R5′ and R6 are described herein.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.